Phathom Pharmaceuticals/$PHAT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Phathom Pharmaceuticals
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
- Ticker
- $PHAT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 371
- Headquarters
- Florham Park, United States
- Website
- www.phathompharma.com
PHAT Metrics
BasicAdvanced
$455M
-
-$1.02
0.50
-
Price and volume
Market cap
$455M
Beta
0.5
52-week high
$18.31
52-week low
$5.02
Average daily volume
1.6M
Financial strength
Current ratio
1.761
Quick ratio
1.67
Long term debt to equity
-1.479
Total debt to equity
-1.598
Interest coverage (TTM)
-0.41%
Profitability
EBITDA (TTM)
-24.984
Gross margin (TTM)
80.68%
Net profit margin (TTM)
-30.19%
Operating margin (TTM)
-9.26%
Revenue per employee (TTM)
$740,000
Management effectiveness
Return on assets (TTM)
-5.44%
Return on equity (TTM)
21.55%
Valuation
Price to revenue (TTM)
1.694
Price to book
-1.34
Price to tangible book (TTM)
-1.34
Price to free cash flow (TTM)
-22.134
Free cash flow yield (TTM)
-4.52%
Free cash flow per share (TTM)
-0.259
Growth
Revenue change (TTM)
86.75%
Earnings per share change (TTM)
-73.09%
3-year earnings per share growth (CAGR)
-35.12%
What the Analysts think about PHAT
Analyst ratings (Buy, Hold, Sell) for Phathom Pharmaceuticals stock.
Analyst projections of the future price of Phathom Pharmaceuticals stock.
Bulls say / Bears say
Second-quarter revenue rose 88% year on year to $74.3 million, while VOQUEZNA prescriptions also grew 88% year on year and 21% from the prior quarter. That points to continued demand growth for the commercial franchise. (Phathom Pharmaceuticals, Inc.)
Operating expenses fell 33% year on year, and Phathom recorded its first operating profit excluding stock-based compensation. It held $182.5 million in cash at quarter-end and expects full-year operating profitability on that adjusted basis. (Phathom Pharmaceuticals, Inc.)
A Phase 3 study is now under way to test VOQUEZNA as an as-needed treatment for non-erosive GERD, building on earlier positive Phase 2 results. The company also completed enrolment in a Phase 2 trial for eosinophilic oesophagitis, creating further potential to expand the franchise if results are positive. (Phathom Pharmaceuticals, Phathom Pharmaceuticals, Inc.)
BDR has sued the FDA, arguing that its decision improperly extends VOQUEZNA tablet exclusivity through May 2032. If BDR succeeds, generic applications could be accepted earlier, putting the franchise’s sales protection at risk. (Phathom Pharmaceuticals)
Phathom cut its 2026 revenue outlook to $310–325 million from $320–345 million after reporting that access and prescribing hurdles deter some doctors from using VOQUEZNA for less severe GERD. This suggests broadening use beyond the patients doctors most readily treat may take time. (Phathom Pharmaceuticals, Inc., Exa)
A competing PCAB, tegoprazan, is expected to enter the US market in 2027. It could challenge VOQUEZNA’s early lead and constrain future market share or pricing. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2026.
PHAT Financial Performance
Revenues and expenses
PHAT Earnings Performance
Company profitability
Upcoming events
No upcoming events
PHAT News
AllArticlesVideos
Funds containing PHAT
Fund name | Fund size | $PHAT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.03% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.